gotop

Technology & Products

New drug development for unmet medical needs

With Vaucarrin® platform, GNTbm has developed nano-gold drugs for the treatment of cancer .  Also, GNTbm is conducting clinical developments of chidamide, a new generation epigenetic regulator, for the treatment of peripheral T cell lymphoma, breast cancer, and other cancers. Through cooperation with China pharmaceutical company Chipscreen. GNTbm more focused on tumor immunotherapy in recent years, hopes to fulfill the demands of unmet medical needs.

  • Immuno-Oncology therapy

    GNTbm has focused on immuno-oncology in recent years. By exploring the dynamic and complex tumor microenvironment, GNTbm has developed the optimal anti-cancer regimen with synergistic effect of combination of both immune checkpoint inhibitor and immune modulator with novel mechanism. Immunotherapy is a novel anti-cancer therapy, which will restart the body’s natural anti-tumor immune response for efficient killing of cancer cells for such a long time, so that there is a chance to make cancer curable or become a controllable chronic disease.

    Read more
  • Vaucarrin
    Vaucarrin®

    Vaucarrin® is a proprietary drug delivery platform developed by GNTbm, which uses GNTbm nano-gold as the core carrier, in combination with effective drugs and targeting agents to form a complex, thereby extending its circulation time in vivo, obtaining effective targeting, and delivering the drug to the diseased tissue or cells.

    Read more
  • Chidamide
    Chidamide

    Chidamide belongs to a new generation of epigenetic regulators and is a highly regarded new type of targeted cancer therapy that is mainly used for the treatment of solid tumors, lymphomas, and other hematopoietic tumors. Furthermore, its epigenetic regulation is a very promising mechanism that can be combined with endocrine drugs to reverse the drug resistance caused by the long-term use of endocrine inhibitors.

    Read more
  • Pipeline
    Pipeline

    GNTbm focuses on the development of licensed-in and in-house drugs. For the licensed-in drug chidamide, GNTbm is to develop the new indications simultaneously with Chipscreen Biosciences, a leading pharmaceutical company in China; and for the in-house pipelines, GNTbm is to develop a series of nano-gold drugs using the proprietary Vaucarrin® nano-gold drug delivery platform.

    Read more
  • R&D

    Read more